anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will include workers between the ages of 18-60 who have neck pain and work at Ölmezler Textile Industry Trade limited company in Van province. Participants will be divided into two groups as experimental and control groups. All participants will receive ergonomic training. In addition, exercise training will be given to individuals in the experimental group. Exercises will be explained individually and will be supported with an exercise brochure. Craniosacral therapy will also be applied to the experimental group and a brochure will be given to teach joint protection principles. Participants will be asked to do the given exercises 3 days a week and continue for 12 weeks. The given exercises will be followed with an exercise follow-up chart. An evaluation will be made before and after the study.
Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.
Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
PURPOSE:To obtain the title composition by blending plant fibers obtained from seed coat of maize with a specific amount of chitosan and a specific amount of alginic acid. CONSTITUTION:Periderm of seed coat of maize seed is treated by any of enzymatic treatment, chemical treatment or physical treatment or a proper combination thereof to give food fibers. 1 pt.wt. of the food fibers is blended with 0.01-1 pt.wt., especially 0.10.3 pt.wt. chitosan and 0.001-1 pt.wt., especially 0.01-0.1 pt.wt. alginic acid. Food fibers obtained by physical treatment of periderm, for example, food fibers prepared by grinding periderm by a grinder such as homogenizer or hammer mill and screening are preferable as the food fibers.
PROBLEM TO BE SOLVED: To provide a taxol submicroemulsion having a low content of a liposome material, a high inclusion ratio, and excellent quality stability in long term storage.SOLUTION: The present invention discloses one kind of taxol submicroemulsion agents. The submicroemulsion agent of the present invention comprises a taxol steroidal compound, an oil for injection, water for injection, an emulsifying agent, an auxiliary emulsifying agent and an isotonic agent. In the introduced taxol steroidal compound, the molar ratio of the taxol to the steroid is 1:0.2 to 4, and 1:0.25 to 2 is preferentially selected. The present invention also discloses a production method and application of the taxol submicroemulsion agent. The steroidal compound is used as an intermediate carrier for improvement in agent oil solubility using the steroidal compound, the taxol steroidal compound is dissolved in an oil phase, and an oil submicroemulsion agent is made in water at pH 3.5-6 with an average particle diameter of 400 nm or less and used for therapy of a malignant tumor. It has higher safety and efficiency.
BACKGROUND/AIM: Immune checkpoint inhibitors can induce immune-related adverse events in various organs, thus careful observation is required.
CASE REPORT: A 69-year-old man was diagnosed with advanced lung adenocarcinoma and treated with combined therapy of carboplatin plus pemetrexed plus pembrolizumab. After two cycles of treatment, anemia was noted. Myelosuppression due to cytotoxic anticancer agents was suspected and the cytotoxic agents were discontinued, followed by three courses of pembrolizumab monotherapy. However, the anemia persisted, requiring red blood cell transfusions. A bone marrow biopsy revealed erythroblast hypoplasia and chromosomal abnormalities, resulting in a diagnosis of pure red cell aplasia. These adverse events were considered immune-related because of the treatment history with an immune checkpoint inhibitor, and 60 mg/day (1 mg/kg/day) of prednisolone was initiated. Anemia improved, and it did not recur during the tapering of prednisolone.
CONCLUSION: Immune-related pure red cell aplasia should be considered for patients presenting anemia during treatment with immune checkpoint inhibitors.
Briefly, the data for this evaluation were collected from adults recruited from the Boston / Cambridge area to participate in an RCT conducted at an eating behavior lab at the Landmark Center (Lab). Participants were masked to the purpose of the study and were randomized to one of four conditions. To conceal the purpose of the study, participants were asked to participate in a pseudo-focus group pretending to conduct consumer research on restaurant preferences. Participants were asked not to eat after 3 pm prior to the 5:30 pm focus group. Participants were seated at individual dining tables and were asked to order and purchase dinner from a restaurant menu and consumed the meal while in the restaurant Lab. After the focus group, participants completed electronic questionnaires (e.g., demographic information, eating behaviors, and perceptions of the meal). Participants returned to the Lab the following day to complete a brief dietary recall interview. After they completed the study procedures, they were debriefed about the purpose of the study and provided the opportunity to withdraw from the study.

The current evaluation will be conducted under an IRB-approved, apriori, statistical analysis plan using the data collected during the Sugar-Sweetened Beverage (SSB) Portion limit Dining Lab RCT.
Sepsis is a life-threatening disease caused by a dysregulated host response to infection, resulting in 11 million deaths globally each year. Vascular endothelial cell dysfunction results in the loss of endothelial barrier integrity, which contributes to sepsis-induced multiple organ failure and mortality. Erythropoietin-producing hepatocellular carcinoma (Eph) receptors and their ephrin ligands play a key role in vascular endothelial barrier disruption but are currently not a therapeutic target in sepsis. Using a cecal ligation and puncture (CLP) mouse model of sepsis, we showed that prophylactic or therapeutic treatment of mice with EphA4-Fc, a decoy receptor and pan-ephrin inhibitor, resulted in improved survival and a reduction in vascular leak, lung injury, and endothelial cell dysfunction. EphA2-/- mice also exhibited reduced mortality and pathology after CLP compared with wild-type mice. Proteomics of plasma samples from mice with sepsis after CLP revealed dysregulation of a number of Eph/ephrins, including EphA2/ephrin A1. Administration of EphA4-Fc to cultured human endothelial cells pretreated with TNF-α or ephrin-A1 prevented loss of endothelial junction proteins, specifically VE-cadherin, with maintenance of endothelial barrier integrity. In children admitted to hospital with fever and suspected infection, we observed that changes in EphA2/ephrin A1 in serum samples correlated with endothelial and organ dysfunction. Targeting Eph/ephrin signaling may be a potential therapeutic strategy to reduce sepsis-induced endothelial dysfunction and mortality.
Group I: the root canal was irrigated with 1 ml of 17% EDTA (Microvem, Istanbul, Turkey), and the solution was kept in the canal for 1 minute. The canal was subsequently irrigated with 2 ml of distilled water and 3 ml of 2.5% NaOCl for 1 minute.
Postural sway has not been investigated before or after a neck exercise intervention in individuals with chronic whiplash-associated disorders (WAD). The aim of the study was to investigate postural sway in individuals with chronic WAD grades 2 and 3: (a) compared with healthy matched controls at baseline; (b) after three months of neck-specific exercise and (c) to investigate the correlation between postural sway with self-reported dizziness during motion and balance problems/unsteadiness. This is a longitudinal prospective experimental case-control intervention study. Individuals with WAD (n = 30) and age- and gender-matched healthy volunteers (n = 30) participated. Postural sway was assessed using an iPhone application. Measurements were carried out at baseline, and for those with WAD a second measurement was performed at the three-month follow-up when neck-specific exercise intervention ended. The WAD group performed significantly worse than the healthy group in both pathway and ellipse area double stance eyes closed at baseline (main outcome), but not at the three-month follow-up. The WAD group significantly improved after rehabilitation in both pathway double stance eyes closed and pathway single stance eyes open. The correlation between postural sway and self-rated dizziness during motion and balance problems was low to moderate. One may conclude that postural sway was improved after a neck-specific exercise programme. The study results strengthen earlier findings that individuals with WAD have worse balance outcome when they have to rely on neck proprioception (eyes closed). The study results may be important for the development of improved rehabilitation methods for WAD.
Participants will be asked to complete the C-SCAT at three of their clinic visits for cancer treatment in addition to usual care for assessing symptoms. This intervention period will last up to about 12 weeks, depending on cancer treatment schedule (for example, every 2, 3 or 4 weeks).
PURPOSE:A hair tonic, applicable to all the phenomena related to hair and scalp, and prepared by mixing an extract solution of Brassica hirta or Brassica nigra in water or an alcohol and an extract of the rind of an orange or lemon. CONSTITUTION:An extract of a seed of Brassica hirta or Brassica nigra is mixed with an extract of the rind of an orange or lemon, egg yolk, perfume and if necessary other materials, e.g. nicotinamide, in water or an alcohol solution, and the resultant solution is allowed to stand in a cool place. A precipitate if formed is filtered to give the titled hair tonic. A water-soluble material is added to an alcohol in portions with constant stirring. EFFECT:The hair tonic is effective for very diverse changes, e.g. baldness and falling hair, without harmful side effects. Useful for recovering color in white hair and preventing the white hair. The hair tonic can be prepared from inexpensive and easily available basic materials without reguiring special equipment.
AIMS: Many patients diagnosed with esophageal cancer have dysphagia from their primary tumor and de novo metastatic disease. The purpose of this study was to test the safety and efficacy of nivolumab given concurrently with hypofractionated chemoradiotherapy to patients with oligometastatic and obstructing esophageal tumors.
METHODS: Patients were enrolled in a planned single-arm, phase 2 clinical trial. Eligible participants had previously untreated oligometastatic (≤5 metastases on fludeoxyglucose-18 positron emission tomography scan outside the primary tumor radiotherapy field) esophageal or gastroesophageal carcinoma, dysphagia, and Eastern Cooperative Oncology Group performance status 0-1. Treatment was with 2 weeks of concurrent hypofractionated radiotherapy (30 Gy/10#) to the primary tumor, weekly carboplatin AUC2, weekly paclitaxel 50 mg/m2, and q2weekly nivolumab 240 mg, followed by nivolumab 480 mg continuing q4weekly until disease progression or 24 months total. A single metastasis was treated with stereotactic radiotherapy (SBRT) (24 Gy/3#) in week 7.
RESULTS: Five patients were recruited before trial closure to new participants for logistical reasons. Existing participants continued treatment per protocol as a pilot study at one center. All five patients completed chemoradioimmunotherapy and SBRT. All patients derived an improvement in their dysphagia. Two patients completed 24 months of nivolumab without disease progression. Grade 3 adverse events (AEs) occurred in 3 patients, however, there were no grade 4 AEs, AEs due to SBRT, or AEs of special interest as defined by the protocol.
CONCLUSION: Pilot results from five patients at one center found that treatment was well tolerated and effective for dysphagia relief. The efficacy of hypofractionated chemoradiotherapy with concurrent checkpoint inhibition should be tested in a multicentre study.
A kind of preparation method for the Traditional Chinese medicine probiotic fermentating metabolism product for preventing and treating piglet bacillary diarrhoea, it is related to preventing and treating piglet bacillary diarrhoea field.(1) preparation of fermentation medium.Dregs of beans, corn flour and natural anti-inflammatory Chinese traditional are mixed with certain proportion, fermentation medium is prepared.(2) biological enzymolysis of fermentation medium.(3) many bacterium collaboration liquid state fermentations.Lactobacillus casei is seeded to fermentation medium, continues to be inoculated with VREF fermented and cultured, inoculates bacillus licheniformis fermented and cultured.(4) solid-state secondary fermentation.(5) low temperature drying.The product total viable count of the present invention reaches 3 × 10 10 CFU/g, in vitro test shows there is the effect that significantly inhibits to Escherichia coli and Salmonella, and piglet feeding shows that product reaches 87.6% to piglet bacillary diarrhoea cure rate.Product direct cost be 0.7 1 ten thousand yuan/it is per ton, market price be 5 10 ten thousand yuan/it is per ton, with higher added value.
Transanal minimally invasive surgery (TAMIS) is a surgical alternative to proctectomy in the management of complex rectal polyps and early rectal cancers. In 2016, our institution introduced a TAMIS programme. The purpose of this study was to evaluate changes in practice and outcomes in our institution in the 3 years before and after the implementation of TAMIS. We conducted a retrospective analysis of a prospective database of patients who underwent proctectomy or TAMIS for the management of complex rectal polyps or early rectal cancers at our institution between 2013 and 2018. 96 patients were included in this study (41 proctectomy vs 55 TAMIS). A significant reduction was noted in the number of proctectomies performed in the 3 years after the implementation of TAMIS as compared to the 3 years before (13 vs 28) ( P  < 0.001); 43% of patients ( n  = 12) who underwent proctectomy in the period prior to implementation of TAMIS were American Society of Anaesthesiologists grade III, as compared to only 15% ( n  = 2) of patients during the period following TAMIS implementation ( P  = 0.02). TAMIS was associated with a significant reduction in length of inpatient stay ( P  < 0.001). Oncological outcomes were comparable between groups (log rank P  = 0.83). Our findings support TAMIS as a safe and effective alternative to radical resection. The availability of TAMIS has resulted in a significant reduction in the number of comorbid patients undergoing proctectomy at our institution. Consequently, we have observed a significant reduction in postoperative complications over this time period.
Inflammation is an essential defense mechanism in which innate immune cells are coordinately activated on encounter of harmful stimuli, including pathogens, tissue injury, and toxic compounds and metabolites to neutralize and eliminate the instigator and initiate healing and regeneration. Properly terminated inflammation is vital to health, but uncontrolled runaway inflammation that becomes chronic begets a variety of inflammatory and metabolic diseases and increases cancer risk. Making damaged tissues behave as "wounds that do not heal" and sustaining the production of growth factors whose physiologic function is tissue healing, chronic inflammation accelerates cancer emergence from premalignant lesions. In 1863, Rudolf Virchow, a leading German pathologist, suggested a possible association between inflammation and tumor formation, but it took another 140 years to fully elucidate and appreciate the tumorigenic role of inflammation. Key findings outlined molecular events in the inflammatory cascade that promote cancer onset and progression and enabled a better appreciation of when and where inflammation should be inhibited. These efforts triggered ongoing research work to discover and develop inflammation-reducing chemopreventive strategies for decreasing cancer risk and incidence.
The present invention relates to a Chinese patent medicine, namely Weibingzhi, which is used for treating various kinds of refractory gastrophy. The cause of gastropathy represents that the intimae of the stomach is infected to generate pathogenic bacteria such as helicobacter pylori, etc. which penetrate in the gastric mucosa to combine with gastric protein to form proteinase, and the proteinase decomposes the gastric protein to secrete harmful substances such as gastric acid, etc. The root cause of gastropathy represents that the intimae of the stomach is injured to form diseases such as carbuncle, ulcers, gastritis, antral gastritis, etc. The weakness of gastropathy represents that disease symptoms of descended extreme hypofunction of the stomach, lowered gastric motility, gastroptosis, etc. occur because of pathological changes. The manifestation of gastropathy represents that depressed vital energy and dyspeptic diseases which are caused by exopathic cause of wind-cold-wetness evil, hungriness, distension, heat, cold, etc. according to an inventor's research, and various kinds of refractory gastropathy are caused by manifestation cause, root cause and actual cause. In conclusion, the Chinese patent medicine has a reasonable and accurate medicine recipe and very strong symptomatic pertinency.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Smilax scobinicaulis C.H. Wright esophagus cancer treatment oral liquid. The oral liquid is a green high-tech Chinese herbal medicine used for treating the esophagus cancer. The oral liquid is a traditional Chinese medicinal oral liquid prepared through the following steps: mixing of Smilax scobinicaulis C.H. Wright, Rhizoma Curcumae, dry root of Stephania tetrandra S., sal ammoniac and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction and concentration. The oral liquid is mainly used for treating the esophagus cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The oral liquid has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The oral liquid fundamentally improves the body functions and prevents cancer cancerization at a low cost in order to recover the health of bodies.
BACKGROUND: Inflammatory bowel disease (IBD) was associated with elevated risk of cardiometabolic diseases in observational studies. We aimed to evaluate the observational and genetic associations of Crohn's disease (CD) and ulcerative colitis (UC) with multiple cardiometabolic outcomes.
METHODS: Our phenotypic and genetic association analyses included more than 400 000 participants who were free of major cardiovascular disease and diabetes at recruitment (2006-2010) and were followed up until December 2019 based on the UK Biobank. For the Mendelian randomization (MR) analyses, 415 and 273 single nucleotide polymorphisms associated with CD and UC, respectively, were selected as genetic instruments. Summary-level data on individual cardiometabolic outcomes were obtained from 4 different genome-wide association studies with a total of 2 248 842 participants.
RESULTS: In the multivariable-adjusted observational analyses, CD was associated with higher risks of heart failure (hazard ratio [HR], 1.72; 95% confidence interval, 1.22-2.42) and type 2 diabetes (HR, 2.11; 95% confidence interval, 1.67-2.67) but not with myocardial infarction or ischemic stroke. UC was related to increased risks of all the assessed cardiometabolic diseases (HRs ranged from 1.29 for myocardial infarction to 1.76 for type 2 diabetes). Conversely, neither the genetic risk score for CD nor that for UC was associated with higher risk of developing cardiometabolic diseases. In 2-sample MR analyses, genetically determined CD and UC were not associated with any of the assessed cardiometabolic diseases (all P values >.05).
CONCLUSIONS: Despite confirming the observational associations, our study does not support a causal association between IBD and elevated risk of cardiometabolic diseases.
A process of purifying a compound of formula I is described.  This process comprises treating an impure reaction product which contains an amount of the compound of formula I and less polar impurities with a hydrophobic resin. Also described is a compound of formula I which is substantially free of less polar impurities, the impurities comprising less than 60ppm, relative to the total weight of the compound. Also described are compounds of formulae II and III. Parenteral compositions that comprise an antibacterially effective amount of the compound of formula I or a salt thereof, where the compound of formula I comprises less than 60ppm of less polar impurities relative to the total weight of the compound are also described. Pharmaceutical compositions that comprise an antibacterially effective amount of the compound of formula II or III, or salts thereof are also described.